Table 1.

Patient demographics and baseline characteristics

Variable	Monotherapy (N = 85)	Combination therapy (N = 18)	Overall (N = 103)
Gender, n (%)
Male	55 (64.7%)	11 (61.1%)	66 (64.1%)
Female	30 (35.3%)	7 (38.9%)	37 (35.9%)
Mean age (years) (mean ± SDa)	49.8 ± 15.94	53.4 ± 16.94	50.4 ± 16.09
Race, n (%)
White	49 (57.6%)	15 (83.3%)	64 (62.1%)
Asian	36 (42.4%)	3 (16.7%)	39 (37.9%)
Country, n (%)
Germany	36 (42.4%)	6 (33.3%)	42 (40.8%)
Korea	28 (32.9%)	3 (16.7%)	31 (30.1%)
Russia	8 (9.4%)	0	8 (7.8%)
Taiwan	6 (7.1%)	0	6 (5.8%)
Greece	0	5 (27.8%)	5 (4.8%)
Other	7 (8.2%)	4 (22.2%)	11 (10.7%)
Mean APACHE II score (mean ± SD)	18.3 ± 8.26 (n = 11)	18.3 ± 2.52 (n = 3)	18.3 ± 7.31 (n = 14)
SOFA score (mean ± SD)	8.8 ± 4.66 (n = 5)	0	8.8 ± 4.66 (n = 5)
Site of Infection, n (%)
Blood	8 (9.4%)	0	8 (7.8%)
Lung	72 (84.7%)	15 (83.3%)	87 (84.5%)
Bone/joint	1 (1.2%)	0	1 (1.0%)
Sinus	0	1 (5.6%)	1 (1.0%)
Liver/spleen	0	1 (5.6%)	1 (1.0%)
Other	2 (2.4%)	0	2 (1.9%)
Multiple	2 (2.4%)	1 (5.6%)	3 (2.9%)
Neutropenic at time of initiation of caspofungin treatment, n (%)
<500 cells/μL	53 (62.4%)	6 (33.3%)	59 (57.3%)
>500 cells/μL	32 (37.6%)	12 (66.7%)	44 (42.7%)
Number of risk factors per patient (mean ± SD)	5.4 ± 1.76	4.8 ± 1.86	5.3 ± 1.78
Risk factors and underlying medical conditionsb, n (%)
Active malignancy	70 (82.4%)	9 (50%)	79 (76.7%)
Immunosuppressive medication	64 (75.3%)	12 (66.7%)	76 (73.8%)
Neutropenia at time of hospitalization	59 (69.4%)	7 (38.9%)	66 (64.1%)
Allogeneic HSCT	18 (21.2%)	5 (27.8%)	23 (22.3%)
Prior fungal colonization	16 (18.8%)	2 (11.1%)	18 (17.5%)
Diabetes mellitus	11 (12.9%)	4 (22.2%)	15 (14.6%)
Organ transplantation	5 (5.9%)	4 (22.2%)	9 (8.7%)
Autologous HSCT	5 (5.9%)	0	5 (4.9%)
AIDS/HIV infection	3 (3.5%)	0	3 (2.9%)

^aSD = standard deviation

^bFrequencies of different risk factors and underlying medical conditions are not mutually exclusive.